During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Naveen Pemmaraju, MD Anderson Cancer Center, Houston, US. We asked, Why does adding navitoclax to ruxolitinib induce responses in patients with relapsed/refractory myelofibrosis?
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Why does adding navitoclax to ruxolitinib induce responses in patients with R/R MF?
Why does adding navitoclax to ruxolitinib induce responses in patients with R/R MF?
Pemmaraju reports the results of a study evaluating the addition of navitoclax to ruxolitinib in 34 patients with myelofibrosis who lost response to ruxolitinib.
Related articles
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox